Corporate Profile
  Share Information
  Financial information
  Press releases
  2011
  2010
  2009
  2008
  2007
  2006
  2005
  2004
  2003
  2002
  2001
  2000
  Presentations
  Shareholder Services
  Event Calendar
  Investor Relations Contact

Crucell's press releases are available via an RSS feed. To add this RSS feed to your reader, right click on the RSS button, click "Copy Shortcut" and add the URL to your feed reader.

RSS

If you are new to RSS, we suggest you read the Introduction to RSS article.

Press Releases


Dutch | German
2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

24 Dec 2002 Centocor returns rights to anti-CD46 antibody to Crucell
23 Dec 2002 Crucell Expects Charge Related to Impairment of Goodwill
20 Dec 2002 Cambridge Antibody Technology and Crucell Settle Patent Dispute
19 Dec 2002 Biotech Alliance of DSM Biologics and Crucell - for faster preparation of new medicines at lower cost
05 Nov 2002 Crucell Appoints Director Corporate Communications
14 Oct 2002 Crucell and the US National Institutes of Health Sign Contract for Production of Ebola, Marburg and Lassa Vaccines for Use in Human Clinical Trials
14 Oct 2002 Crucell Revenues EUR 2.0 million in Third Quarter 2002
04 Oct 2002 Invitation Conference Call Q3 Results 2002
03 Oct 2002 Crucell to Webcast Presentation at UBS Warburg Global Life Sciences Conference
01 Oct 2002 Crucell and Applied Molecular Evolution Sign PER.C6(TM) Antibody Production Agreement
09 Sep 2002 Crucell announces management changes
05 Sep 2002 Crucell Signs PER.C6(TM) Agreement with NatImmune
16 Aug 2002 Crucell and Johns Hopkins Announce Research Agreement for Antibodies against LCH
12 Aug 2002 Crucell Signs PER.C6(TM) Licensing Agreement with GenVec
07 Aug 2002 Crucell and NIH Extend Ebola Vaccine Agreement to include Marburg and Lassa Vaccines
19 Jul 2002 Crucell Appoints Dr. Jaap Goudsmit to Executive Committee
15 Jul 2002 Crucell Increases Second Quarter 2002 Revenues by 131%
08 Jul 2002 Crucell maintains earlier profit statements
03 Jul 2002 Crucell and Genexine Announce Agreement
04 Jun 2002 Crucell to Webcast Presentation at the Needham & Company Biotech Conference
29 May 2002 Crucell signs PER.C6TM license with MedImmune
16 May 2002 Crucell and NIH to develop ebola vaccine
15 Apr 2002 Crucell's first quarter 2002 revenues increase 135%
10 Apr 2002 Rhein Biotech and Crucell enter into PER.C6 License agreement
05 Mar 2002 Crucell: preliminary Phase I data of PER.C6-derived HIV vaccine encouraging
04 Mar 2002 Crucell spin-out Galapagos Genomics NV to complete a private placement
01 Feb 2002 First milestone achieved in Centocor-Crucell agreement for CD46 human antibodies against cancer
24 Jan 2002 Invitation Conference Call Annual Results
23 Jan 2002 Crucell and Innogenetics announce PER.C6 deal for the development and manufacturing of antibodies
17 Jan 2002 Crucell appoints VP Development and Regulatory Affairs
15 Jan 2002 Lexigen signs on as Crucell's 19th PER.C6 licensee
10 Jan 2002 PER.C6 manufacturing services available in United States